Tfc Financial Management Beam Therapeutics Inc. Transaction History

Tfc Financial Management

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$30.15 - $48.79 $24,572 - $39,763	815 Added 384.43%	1,027 $31,000
Q3 2022 Oct 21, 2022	SELL	$39.79 - $70.31 $20,611 - $36,420	-518 Reduced 70.96%	212 $10,000
Q1 2022 May 04, 2022	BUY	$53.73 - $82.16 $8,596 - $13,145	160 Added 28.07%	730 $42,000
Q4 2021 Feb 02, 2022	BUY	$68.02 - $99.06 $20,406 - $29,718	300 Added 111.11%	570 $45,000
Q3 2021 Nov 02, 2021	SELL	$84.37 - $133.6 $1,603 - $2,538	-19 Reduced 6.57%	270 $23,000
Q2 2021 Jul 29, 2021	SELL	$64.12 - $128.71 $3,462 - $6,950	-54 Reduced 15.74%	289 $37,000
Q1 2021 May 03, 2021	SELL	$71.28 - $120.75 $1,425 - $2,415	-20 Reduced 5.51%	343 $27,000
Q4 2020 Feb 10, 2021	BUY	$22.24 - $95.63 $8,073 - $34,713	363 New	363 $30,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Tfc Financial Management, based on Form 13F filings with the SEC.

Stay updated on Tfc Financial Management with notifications on news.